Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPTR-1-201 in Advanced Solid Tumors
NCT07293754Phase 2Recruiting
- Sponsor
- Repertoire Immune Medicines
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells
- Countries
- 4
01
Overview
A Phase 2 trial of RPTR-1-201 in solid tumor, sponsored by Repertoire Immune Medicines. Started Dec 2025; status: recruiting.
02
Drugs
RPTR-1-201
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07293754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07293754.